Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients

Probiodrug to attend International Conferences in January 2017
Probiodrug to attend and present at International Conferences in February 2017